Bloom Public Health’s Post

Join us tomorrow for an insightful session on the Kenya National Pharmaceutical Policy #pharmaceuticalpolicy

A relevant and important event for the Ukrainian medical and pharmaceutical business in Poland will take place on June 20 in Warsaw on the initiative of Oleksandr Torhun. The round table with the participation of the owners will discuss the problems and how businesses in Poland in the medical and pharmaceutical sectors coped with them. Join the initiative of the committee for the promotion of medical and pharmaceutical business to discuss at a round table about "Access to foreign markets and the export potential of Ukrainian medical and pharmaceutical business"! #Ukraine #Poland #pharma #business

Bloomberg TV Mongolia explored the German pharmaceutical sector, considering its historical #significance and current market #dynamics. With projected exports of $126.01 billion in 2022, Germany maintains its position as a major player in the global pharmaceutical industry alongside the United States. From its historical role as a global hub between 1900 and 1930 to its current contributions, Germany continues to shape the pharmaceutical landscape on a global scale. #DenkPharma #QualityMadeInGermany

Check out our latest publication: "Revision of the General Pharmaceutical Legislation: Impact Assessment of Key Orphan Proposals on Member States". https://bit.ly/3JPQxb0 Though the revision of the General Pharmaceutical Legislation targets EU-level frameworks and processes, proposed changes are sure to have immediate as well as downstream consequences at the country level. This paper in collaboration with Sanofi explores these potential consequences, focusing on a selection of proposals by the European Commission aimed at improving access and affordability of orphan products. Key findings highlight: - Risks to future orphan development and availability in Europe via proposed reductions in key incentives (although these may help bring down prices in the short term). - Challenges with the calibration and predictability of conditional supplementary incentives aimed at encouraging orphan development in areas of high unmet need and faster launch of medicines across Europe. - Potential impact on national pricing and reimbursement processes due to changes impacting evidence availability, and risk that this fails to align with country needs and priorities.   - The revised Legislation that is ultimately adopted will set the stage for the European pharmaceutical market for decades to come, particularly for orphans which are more reliant on incentives to be viable for development and launch in the region. It is therefore critical that revisions are calibrated to meet Member States’ needs and assure future availability of these products in Europe. Authored by Isabelle Laurence, Emilie Neez and Elena Nicod.   #EUPharmaLegislation #EuropeanCommission #OrphanMedicines #Dolon

With less than 2 weeks remaining, Ahmed I Yakasai, mni, FPSN Former President of the Pharmaceutical Society of Nigeria and Chairman of Pharma West Africa, invites you to join the conversation. Delve into the insights that make Pharma West Africa a pivotal event in the pharmaceutical industry. Register now and ensure you're part of this enlightening experience! 💼🌍 https://lnkd.in/djeJ8xJw #PharmaWestAfrica #RegisterNow #IndustryInsights

On Wednesday, the European Parliament’s ENVI committee adopted its position on amendments to the EU pharmaceutical directive and regulation. These revisions are aimed at bolstering innovation and competitiveness within the European pharmaceutical sector, while also ensuring equitable access to medications across the region.   The adopted position, though less extensive than the European Commission's original proposals, carries significant implications for pharmaceutical organisations operating in Europe. Anne Dhulesia and I outline the position adopted by the European Parliament, including details on changes to exclusivity periods for orphan and non-orphan drugs. #europeanpharma #orphandrugs #pharmaindustry #europeanpharma

Happy with the selection of speakers this version of Pharmaconex

The Tanzania Pharmaceutical Market size is at around US $ xx Bn in 2021 and is projected to reach US $ xx Bn in 2030, exhibiting a CAGR of xx% during the forecast period. Tanzania Pharmaceutical Market Size (In USD Bn) (2021-2030F) #pharmaceuticals #Tanzania #Globalbusinessdevelopment

A course well worth attending! Learning from experts and industry leaders!

🌍 Building a Competitive & Innovative Pharmaceutical Ecosystem for the EU 🏥 📣 Chiesi-Group is proud to join innovative pharmaceutical companies in signing EUCOPE - European Confederation of Pharmaceutical Entrepreneurs’s open letter to EU Institutions and Member States, calling for a future-proofed ecosystem that allows innovation, research, and access to cutting-edge therapies, including for #rarediseases. 💡 Together, we call on the leaders of the EU Institutions to take decisive action, ensuring the EU leads the way in pharmaceutical innovation on the global stage. A stronger, more supportive ecosystem will enable groundbreaking advancements that improve patients’ lives across Europe and beyond. #PharmaInnovation #EUPharma #InnovationEcosystem Read the open letter here: https://lnkd.in/eCeJk8U5